How to Cite:

Sharma, A., Chanan, R., Patil, K., & Dwivedi, S. (2022). COVID-19 vaccine's knowledge, attitude, and perception of healthcare students in India after the second wave of a pandemic: An online questionnaire-based survey. International Journal of Health Sciences, 6(S6), 10907-10929. https://doi.org/10.53730/ijhs.v6nS6.12959

COVID-19 vaccine's knowledge, attitude, and perception of healthcare students in India after the second wave of a pandemic: An online questionnaire-based survey

Ashaben Sharma, Ph.D.Scholar, MS, PGDCRM, M.Sc.

Department of Clinical Research, Himgiri Zee University, Dehradun, India *Corresponding author email: ashashrma9786@gmail.com

Dr. Ritika Chanan, Ph.D., M.Sc.

Department of Clinical Research, Himgiri Zee University, Dehradun, India

Dr. Kiran Patil, Ph.D., M.Pharm

Department of Clinical Research, Himgiri Zee University, Dehradun, India | Smt S.S. Patil College of Pharmacy, Jalgoan, India

Shivam Dwivedi, Ph.D. Scholar, MA, B.Sc.

Lakshmibai National Institute of Physical Education, Gwalior, India

Abstract---Background: The COVID-19 vaccine has been increasingly discussed in India since its first approval in January 2021, prioritizing healthcare workers including healthcare students. Since healthcare students (future healthcare workers) play a vital role in vaccination coverage, this study aimed to assess the knowledge, attitude, and perception toward the COVID-19 vaccine of healthcare students after the second wave of the Pandemic. Method: A web-based questionnaire survey tool was developed, delivered over "Google Forms", and was filled out randomly among the intended population in many states of India after the COVID-19 pandemic second wave. The questionnaire contained an informed consent form along with questions related to socio-demographics, knowledge, attitude, and perception, toward the COVID-19 vaccine. The data was collected in excel and based on the result we prepared our statistical graphs. Multivariate regression and Bivariate were utilized to identify differences among subgroups with diverse sociodemographic characteristics. Result: Most students had below-average knowledge regarding the COVID-19 vaccine. The highest percentage of correct responses were from postgraduate medical students living in urban areas and the lowest was from undergraduate nursing students living in rural areas. Most

Manuscript submitted: 9 May 2022, Manuscript revised: 18 July 2022, Accepted for publication: 27 August 2022

International Journal of Health Sciences ISSN 2550-6978 E-ISSN 2550-696X © 2022.

participants could not identify the names of all approved vaccines in India and only (18%) of participants identified the correct timeframe to wait for receiving optimal protection from the COVID-19 vaccine. Doctors, mass media, social media, and professors/ teachers were the most common source of information. Almost all participants agreed to suggest the COVID-19 vaccine to their prospective patients and had favorable opinions regarding vaccinations. However, only 37% of participants considered themselves "pro" toward the COVID-19 vaccine. Conclusion: This study among Indian healthcare students reflects inadequate knowledge with many misconceptions, a positive attitude, and moderate perception towards the COVID-19 vaccine,

consequently, emphasizing the need for an effective educational-based intervention to disseminate accurate information regarding effectiveness and safety to promote the COVID-19 vaccine uptake in the future.

Keywords---COVID-19, healthcare, vaccination, students, knowledge, attitude, perception.

Introduction

The World Health Organization (WHO) announced the "Corona Virus Disease 2019" widespread to be a global health emergency [1], due to the SARS-CoV-2 virus's speedy spread across 200 countries, which has resulted in more than a million deaths and tens of millions of affected individuals worldwide. The epidemic has also harmed the global economy and national healthcare systems. Considering the COVID-19 pandemic, India, the second-most populous nation in the world (1.34 billion people), must pay more attention to its present healthcare delivery systems, which have been plagued by issues with pricing and accessibility. Additionally, the second wave of the epidemic has resulted in an unprecedented number of hospital admissions and fatalities [2], resulting in a severe humanitarian disaster. Currently, mass vaccination against COVID-19 has appeared as a crucial preventative measure since there are no known antiviral therapies specifically for COVID-19 [3].

In an extremely unusually short period, India has already licensed seven vaccine candidates for use against COVID-19 for emergency use [4]. Healthcare personnel and healthcare students were given priority in the first roll-out of vaccination. A documented body of data from earlier research studies points to the vaccination of healthcare workers as one of the most potent and economically viable health strategies to reduce the likelihood of cross-transmission and thereby restrain the development of epidemics [5]. The continuing epidemic has shown that, in addition to healthcare professionals, healthcare students may contribute significantly as volunteers to healthcare systems in times of crisis. In the fight against the pandemic, vaccinated members of the future healthcare workforce (healthcare students) can remain on the front lines, responsible for recommending vaccination and giving advice to their future patients, as well as serving as advocates for a more extensive vaccination program for younger generations. To pave the road for better vaccination coverage rates, immunizing healthcare students on a priority basis is consequently crucial.

There was a lot of reluctance when the COVID-19 immunization program was introduced in India on 16th January 2021, for front-line healthcare personnel [6]. Even though a lot of effort is being put into creating and distributing COVID-19 vaccines, uncertainty over their acceptability is one of the major obstacles to effective COVID-19 immunization [7]. Decision-making about vaccine acceptability is likely influenced by several variables, including more information, a positive outlook, an awareness of how illnesses spread, and the potential advantages of vaccination [8,9]. Health care students' future infection control practices and the transmission of illness may be directly impacted by their limited understanding of and wrong attitudes concerning the COVID-19 vaccine [10]. Students studying health care who have a background in education and a basic comprehension of COVID-19 may contribute

significantly by raising community members' awareness of the gravity of the pandemic crisis [11]. The study conducted among 310 medical students in one hospital in Germany discovered that enhanced knowledge eventually affected willingness to take vaccination [12]. One of the studies conducted on Canadian medical, pharmacy, and nursing healthcare detected a considerable association between a positive attitude and improved knowledge [13]. It is advised that knowledge of the obstacles and facilitators of vaccination should be assessed before any intervention is designed to promote vaccine uptake. The outcome of the next vaccination trials will also be determined by the healthcare professionals' approval of the COVID-19 vaccine [14, 15]. Worldwide, medical students and other healthcare professionals have been extensively examined concerning vaccine reluctance [16]. However, In India, there is currently not enough research available on healthcare students' knowledge, attitude, and perception regarding COVID-19 vaccination, especially after the second pandemic wave, even though many other studies are being carried out all over the globe. To adopt the most efficient intervention plan to increase vaccine coverage during the campaign, it is essential to comprehensively assess the knowledge, attitude, and perception of future healthcare professionals (healthcare students) about COVID-19 immunization.

Method and Materials

Study design and participants

From December 2021 to January 2022, an online-based cross-sectional survey was carried out using a "Google Form" to collect answers from undergraduate and postgraduate healthcare students, currently enrolled in any of the government, private, or deemed universities of India, who had net access, could deliver informed consent, and understand the English language. For sample size, based on the past study [17], for the power of 80% level significance of 5%. along with the dropout rate, the desired sample size was 596 healthcare students.

Ethical consideration

The survey was carried out under the ethics of the Declaration of Helsinki. The informed Consent Form, questionnaire, and study protocol were reviewed and approved by the Institutional Ethics Committee (Sangini Hospital Ethics Committee, Reg. No. ECR/Ist/147/GJ/2013). Before participating in the Survey, Informed consent was taken from each interested participant. All study participants' confidentiality was kept by making their data anonymous.

Tool development, authentication, and distribution

A questionnaire (in the English language) was formulated using an extensive literature review, and fact sheets, by eliciting the opinion of subject experts, prior literature, and information booklets on COVID- 19 formed by the Indian Health Ministry, CDC, and WHO. The survey tool was first created and validated to pretest the questionnaire among a small group of 5-10 chosen experts for importance, clarity, and acceptance. Multiple choice questions were included in the survey's final questionnaire took 5 to 10 minutes to complete. The survey was composed of two components: an informed consent form, and a questionnaire form. The questionnaire form was comprising questions regarding, socio-demographic characteristics knowledge perception, and attitude toward the COVID-19 vaccine. The final survey link was sent to the healthcare students through multiple media channels, including Gmail and WhatsApp, in the form of a "Google Form." By completing the informed consent form and responding to an agree/disagree question, each subject willingly decided to participate in the research. All the participants' anonymity was ensured, and the privacy of the data will be confidential.

Socio-demographic characteristics information

All participants' sociodemographic data, including gender, age residence area, household income, academic stream, direct/indirect contact with COVID-19 patients during coursework, any pre-existing medical comorbidities, past vaccination history, and any record COVID-19 diagnosis were collected through 13 questionnaires.

Knowledge, attitudes, and perceptions

A total of 14 items tried to incorporate important questions including 10 items for knowledge mainly focused on knowledge about the infection, vaccine, self-rating to have COVID-19 vaccine knowledge, understanding, current source of information; 2 items for attitude; 2 items for perceptions, concerns, and its risk-benefits. A point was added to the final score for each right response. Each section included a 5-point Likert scale (strongly disagree to strongly agree), multiple choice questions (select one/ more than one option) and forced-choice questions (yes/no/I don't know) items. The 'yes' response was coded as 1, while the 'No/I Don't know responses were conducted as 0. Few questions had possible responses to choose correct options and true/false options A correct answer was assigned one point, and an incorrect/unknown answer was assigned 0 points.

Study hypothesis

- H1: There is a significant difference of Socio-demographic characteristics on knowledge and/or attitude and/or perception about COVID-19 vaccination.
- H0: There is no significant difference of Socio-Economic characteristics on knowledge and/or attitude and/or perception about COVID-19 vaccination.

Data analysis and statistical consideration

Data was gathered utilizing snowball sampling via a web-based (anonymous) questionnaire survey. To maintain its correctness, all the gathered data was put into Excel and double-checked to eliminate any errors. Reading, summarizing, extracting, and encoding the data and statements connected to the research objectives were used to conduct data analysis. Then, the excel sheet was introduced into SPSS software to comprehend the findings of the statistical analysis, constant variables. The frequencies and proportions were determined using descriptive statistics. (i.e., means, standard deviations percentages, frequencies). To analyze the connections between co-variates and to gauge the degree of correlation among study variables, chi-square tests, one-way ANOVA tests, and multivariable logistic regression was used. Statistical significance was considered to exist if the *P-value* was lower than 0.05.

Result

Socio-demographics characteristics

A sum of 596 students from various states of India took part in the survey (Table 1). About two-thirds of participants (57.4%) were from living in rural parts of India (Figure 1).




Figure 1. Response distribution of Question 4. "What best characterizes the area where you live"

The student's gender was almost evenly distributed (44.6% females). The majority (94.8%) of students were between of age 18-24 and had income capita of below 50,000 INR (62.6%). Most students were studying in the undergraduate pharmacy, followed by the nursing and medical stream (Table 1). Almost half of the students (52%) were not involved indirectly or directly in taking care of COVID-19-infected patients during the course work. Approx. 63% of students did not have any premedical conditions. Approx. 60% of students did not vaccinate for or remember past vaccination. The students (40%) who had the past vaccinations have majorly been vaccinated for (Polio= 70. %, Tuberculosis (23%), and others). Most students did not have a COVID-19 diagnosis, but they personally knew family or friends who had COVID-19 impact (Figure 2).




Figure 2. Response distribution of Question 14. "To your knowledge, please select the option which is applicable for the below statements?"

Participants' Socio-demographic characteristics details were depicted in Table 1. Applying only variables that were statistically significant in the bivariate analysis (P - value < 0.05), adjusted multiple regression maintained having a degree of academic stream and living area as significant predictors of knowledge, attitude, and perception.

| Table 1. So | cio-Demographics Cha | racteristics of tl | ne participants |
|-------------------|--------------------------------------|--------------------|-----------------|
| | Variables | Frequency | Percentage |
| Gender | Male | 331 | 55.40% |
| Gender | Female | 265 | 44.60% |
| | 18-24 | 565 | 94.80% |
| Age Group | 25-34 | 26 | 4.40% |
| Globb | 35-44 | 5 | 0.80% |
| Residence | Rural | 342 | 57.40% |
| Area | Sub-urban | 76 | 12.80% |
| Alica | Urban | 178 | 29.90% |
| | 100,000 to 300,000 INR | 44 | 7.40% |
| | 300,000 to 500,000 INR | 28 | 4.70% |
| Income | 51,000-100,000 INR | 115 | 19.30% |
| | Above 500,000 INR | 36 | 6% |
| | Below 50,000 INR | 373 | 62.60% |
| | Medical | 21 | 3.50% |
| Academic | Nursing | 48 | 8.10% |
| Stream | Pharmacy | 519 | 87.10% |
| | Other allied science | 8 | 1.30% |
| Current | Postgraduate / Master's degree | 56 | 9.40% |
| Academic Study | Undergraduate / Bachelor's degree | 540 | 90.60% |

Knowledge regarding COVID-19 vaccine

The allocation of every COVID-19 vaccine-related knowledge category is presented in Table 2. Without implementing correlation variables, overall, we found most of the participants were not much knowledgeable of COVID-19 vaccines approved in India except COVAXIN and COVISHEILD (Figure 3).




Figure 3. Response distribution of Question 14. "Which of the following COVID-19 vaccine(s) have you heard of? (Select more than one options that apply)"

As mentioned in Figure 4, only 18.3% of participants correctly identified the time to receive optimal protection from the vaccine





Figure 4. Response distribution of Question 16. "How long do you have to wait to receive optimal protection from the COVID-19 vaccine?"

Apart from 64.2% of respondents, other participants were confused about the scheduling/number of the COVID-19 vaccine. Statements regarding COVID-19 vaccine knowledge were not correctly reported. Most respondents failed to identify the vaccines' correct types. The mean score of knowledge is noticed for all the COVID-19 vaccination knowledge in the range of 5 and found to be significantly better among the respondents who reported having a higher healthcare degree post graduate medical, living in urban/suburban areas, (Table 3, Bar Graph 2). The respondent who had been detected with COVID-19 infection earlier agreed that they can still get COVID-19 after having been vaccinated against COVID-19 (Bar Graph 1).



Bar Graph 1. Dependent variables of knowledge regarding the COVID-19 vaccine

Additionally, Table 2 reveals the participants' sources of knowledge on the COVID-19 vaccine, which are mostly from the mass media news, and online social media. As mentioned in Figure 5, more than half of the respondents did not attend any lectures/discussions about the COVID-19 vaccine which draws attention.







Figure 5. Response distribution of Question 22" Have you attended any of the discussions/ lectures regarding the COVID-19 vaccine?

| Socio-demography | Sum of | E | Mean | | |
|------------------|---------|----|--------|-------|-------|
| factors | Squares | df | Square | F | Sig. |
| Residence | 7.081 | 2 | 3.54 | 4.786 | 0.009 |
| Area | | | | | |
| Academic | 4.257 | 2 | 2.128 | 2.877 | 0.043 |
| Stream | | | | | |
| Household | | | | | |
| Income Per Year | 7.329 | 4 | 1.832 | 2.477 | 0.047 |








Attitude toward COVID-19 vaccine

Table 4 displays the allocation of each attitude component about the COVID-19 vaccination. The median score of attitudes had a 79 % "good attitude" rating overall. However, even though only about a quarter of those questioned feel that COVID- 19 should be mandatory for children under 18 years of age. Nearly 80% of those surveyed agreed that it is their responsibility to learn about the COVID-19 vaccine as future healthcare workers and that the COVID-19 vaccination should be compulsory for all healthcare workers as well as healthcare students. Regulated multiple regression, which only considers factors that are statistically significant in bivariate analysis, found that participants, highly educated

(medical/pharmacy/postgraduates), and residing in urban/suburban areas had considerably higher mean attitude scores significant predictors of attitudes (Bar Graph 4). As per Bar Graph 3, 57.6% of healthcare respondents who personally knew someone in their family, friends, or community groups who became extremely sick or died, agreed that they will listen to their healthcare provider or doctors' advice regarding the COVID -19 vaccine.



l personally know anyone in my family, group of friends, or community networks who became seriously ill or died

Bar Graph 3. Dependent variables of attitude regarding the COVID- 19 vaccine

However, as mentioned in Figure 6, only 37.4% of respondents described themselves as "Pro-vaccination" which indicates community health measures are necessary to impact attitudes toward the COVID-19 vaccine in a favorable direction.





Figure 6. Response distribution of Question 25. "Would you describe yourself as being pro-vaccination or anti-vaccination or neutral?"

Table 5 Univariate Tests; Dependent variables of attitude regarding the COVID- 19


| | V | accine | | | |
|------------------------------|-------------------|--------|----------------|-------|-------|
| demography | Sum of Squares | | Mean Square | F | Sig. |
| Residence Area | 6.143 | 2 | 3.071 | 4.630 | 0.010 |
| Academic Stream | 10.123 | 2 | 5.062 | 7.631 | 0.001 |
| Household Income Per Year | 6.958 | 4 | 1.740 | 2.623 | 0.034 |



Bar Graph 4. Estimated marginal means of COVID- of attitude regarding the COVID-19 vaccine

Perception toward COVID-19 vaccine

Table 6 indicates that quarters of respondents weren't sure that the advantages of the COVID-19 vaccine overshadow the risks or side effects, or life can be "pre-COVID-19" after "post-COVID-19 vaccination". The correlation analysis revealed that most of the participants agreed that the recently launched COVID-19 vaccination could help to boost the body's natural defenses (81.2 %) had COVID-19 diagnosis in the past (Bar Graph 5). Descriptive statistics of all perception parameters established those urban residents had a considerably better sense of perception than rural residents (*P-value* < 0.05). Among pharmacy respondents compared to nursing, over 80% responded that the COVID-19 vaccine is essential for them to remain healthy as future health care workers and important for overall communities. Regarding the question (Bar Graph 6), Over half (52%) of the participants said that they should stop wearing masks, avoid using hand sanitizer and that there is no need to keep their social distance.



Bar Graph 5. Dependent variables of attitude regarding the COVID-19 vaccine





Figure 7. Response distribution of Question 26. "Does getting a COVID-19 vaccine indicate that you should stop"

Table 7 Univariate Tests; Dependent variables of perception regarding the COVID-19 vaccine

| Socio- | Sum of | | Mean | | |
|------------|---------|----|--------|-------|-------|
| demography | Squares | df | Square | F | Sig. |
| factors | | | | | |
| Residence | 2.244 | 2 | 3.122 | 1.680 | 0.037 |
| Area | | | | | |
| Academic | 2.812 | 1 | 2.812 | 4.213 | 0.041 |
| Stream | | | | | |
| Household | | | | | |
| Income Per | 3.683 | 2 | 1.841 | 2.759 | 0.064 |
| Year. | | | | | |



Bar Graph 6. Estimated marginal means of perception regarding the COVID-19 vaccine

Hence, from the above Tables and Graphs, it can be concluded that since *P*-value is lesser than 0.05 for all mentioned factors of socio-economic determinants, hence we accept an alternate hypothesis i.e., There is a significant difference between Socio-demographics determinants on Knowledge, attitude, and perception towards COVID-19 vaccination. Table 8 represents the overall correlation among attitude, knowledge, and perception of the participants and exhibited a highly significant positive relationship between knowledge, attitude, and perception (P- value < 0.05).

| Table 8 | | | | | | | | | | | | |
|----------------------|------------------------|---------------|------------|------------|--|--|--|--|--|--|--|--|
| Correlati | ons between know | ledge, attitı | ide, and p | erception | | | | | | | | |
| | | Knowledge | Attitude | Perception | | | | | | | | |
| | Pearson Correlation | 1 | .570** | .494** | | | | | | | | |
| Knowledge | Sig. (2-tailed) | | .000 | .000 | | | | | | | | |
| | Ν | 596 | 596 | 596 | | | | | | | | |
| | Pearson Correlation | .570** | 1 | .612** | | | | | | | | |
| Attitude | Sig. (2-tailed) | .000 | | .000 | | | | | | | | |
| | N | 596 | 596 | 596 | | | | | | | | |
| | Pearson Correlation | .494** | .612** | 1 | | | | | | | | |
| Perception | Sig. (2-tailed) | .000 | .000 | | | | | | | | | |
| | Ν | 596 | 596 | 596 | | | | | | | | |
| **. (2-tailed) Corre | lation is significan | t at the 0.0 | 1 level. | | | | | | | | | |

Discussion

The COVID-19 vaccine is found to be the most ideal answer to the pandemic. Even though the Indian government already has begun the COVID-19 vaccine roll-out [18], the immunization of COVID-19 raises questions regarding the acceptability of vaccinations in this nation. Since, patients often believe healthcare professionals for reliable data about vaccines and vaccine-inevitable diseases, healthcare professionals' knowledge, attitudes, and perceptions towards the COVID-19 vaccine after the second wave's tragic impact were questionable. The future healthcare workforce (healthcare students) with higher knowledge, positive attitudes, and a good perception toward vaccinations are more expected to advise vaccinations to their future patients. This paper introduces important outcomes by evaluating the knowledge, attitudes, and perceptions among healthcare students towards COVID-19 vaccinations after the second pandemic wave in India. The findings indicate many socio-demographic components persuading knowledge, attitudes, and perceptions towards COVID-19 vaccine and thus can acts as a guide for Indian health ministries and community health to develop COVID-19 vaccine awareness health education programs and targeted education-based intervention.

More than half of the students were found to have poor knowledge of the COVID-19 vaccine. In this research, the healthcare degree domain, residence area, family income, and prior vaccination history were all strongly correlated with knowledge. There was no substantial gender difference found in participants' knowledge regarding the COVID-19 vaccine, however, research carried out in Bangladesh on knowledge of COVID-19 disease suggested that males achieved somewhat higher than average than females on knowledge exams. Participants with no prior history of COVID-19 and neither witnessed close family/friends having COVID-19 were found to be had less knowledge about the vaccine. They were worried about the possible side effects of getting a vaccine and exhibit a negative attitude toward the COVID-19 vaccination. Participants who had a higher level of knowledge also believed that they would wear masks, and maintain social distance, even after getting COVID-19 vaccination. Significantly, most medical and Pharmacy students (79%) had a favorable opinion toward the COVID-19 vaccination than other participants (nursing and other alliance science), which is also supported by earlier research conducted in China demonstrating that individuals with a higher educational (medical) background demonstrated more knowledge and good attitude regarding COVID-19 then the non-medical background [19].

The living area and level of healthcare study domain had a significant connection with attitude toward getting vaccinated against COVID-19. We found that more than half (52%) of the respondents thought that everyone in India should get the COVID-19 vaccine. Additionally, individuals in our research, who had all the required immunizations earlier in childhood had higher favorable views regarding receiving COVID-19 shots. Our findings are in line with a study from Hong Kong that found past vaccination history to be one of the key factors influencing the inclination to get the influenza vaccine [20], which was additionally endorsed by a previous study from China [21]. In our study, 30.7% feels that it's their responsibility as future health care worker to learn about COVID -19 vaccines for themselves and their future patients. 45.6 % of participants responded that they would do what their doctor or health care provider recommends about the COVID -19 vaccine. One of the correlations was discovered that students found with high knowledge were the ones who attended lectures/sessions on COIVD-19 vaccination from colleges got source and information from colleges teachers/professors on COVID-19 vaccine. The variations in awareness of COVID-19 vaccinations that we discovered in our research may be caused by a lack of healthcare professional recommendations or information about COVID-19 vaccines since the vaccine distribution began. Concerns regarding the safety of vaccines may also be diminished by the probable underreporting or misinterpretation of data on COVID-19 mortality and incidence severity [22]. Therefore, it is crucial to assist members of the community by giving them simple access to reliable, information on vaccines.

Vaccinology does not happen in the curricula of most Indian healthcare colleges' education programs in-depth; this study provides insightful information on educational awareness about COVID-19 vaccination to include at all levels of healthcare education [23]. If we freeze the correlation of the sociodemographic variables, the overall results revealed that most students establish a positive attitude and average perception toward the COVID-19 vaccine. Holding in mind the earlier mentioned findings that the participants showed in general positive attitudes toward vaccination, we can be understandably hopeful in believing that they will be crucial advocates and promoters of the vaccination practice.

Conclusion

In conclusion, our study discovered inadequate knowledge regarding the COVID-19 immunizations among future healthcare workers in India although attitude was found to be more positive with an average level of perception. The identified knowledge gaps found in this study suggest introducing a targeted educational inclusive specialized vaccination curriculum at both the postgraduate and undergraduate levels of healthcare studies emphasizing the importance of their knowledge, attitude, and perception regarding the vaccines so students can provide correct information to their future patients. To lessen the vaccine reluctance enabled and promoted by false information in the media, the relevant health authorities and policymakers should immediately disseminate and publicize health education programs and more precise information which will also help in developing appropriate vaccination strategies for broader coverage of the population.

Strength and Limitation

Data discovered here will assist to detect viable issues to be focused on to make sure the vaccine's sufficient acceptance by this group and support the advancement of learning programs to educate skills to promote and deliver vaccine recommendations to the future vaccine-hesitant communities. Our survey had the limitation that it was performed amid the third wave when COVID-19 vaccination had started among healthcare students. Therefore, it could have underrated the initial vaccine attitude of those who consequently switched to a good attitude and were ultimately vaccinated. Furthermore, the survey was performed among healthcare students so do not know if the outcomes can be generalized to healthcare professionals or members of the public at lower risk of COVID-19.

Financial Relationship

The authors have acknowledged that no financial funding was collected from any organization.

Other Relationship

All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Animal Subjects

The authors have verified that this research did not include animal tissue or subject.

Conflict of Interest

The authors proclaim that they have no conflict of interest.

Informed consent statement

Informed consent was obtained from all subjects involved in the study.

Data availability statement

The data produced and evaluated during the existing study are not openly accessible due to confidentiality and privacy contracts as well as other limitations but are presented by the author with a satisfactory application.

Acknowledgment

We are thankful to all participants for taking part in this study.

References

- Almaghrabi RS, Omrani AS. Middle East respiratory syndrome coronavirus (MERS-CoV) infection. British Journal of Hospital Medicine. 2017 Jan 2; doi: 78(1):23-6.
- 2. Bennett RG. Influenza vaccination of health care workers in long- term-care hospitals reduces the mortality of elderly patients. Journal of the American Geriatrics Society. 1997; doi:45(7):898-9.
- 3. Betsch C, Wicker S. E-health use, vaccination knowledge and perception of own risk: drivers of vaccination uptake in medical students. Vaccine 2012; doi: 30(6):1143-8.
- 4. Callaghan T, Moghtaderi A, Lueck J, Hotez P, Strych U, Dor A, et al. Correlates and Disparities of COVID-19 Vaccine Hesitancy. SSRN Electron J. 2020. doi:10.2139/ssrn.3667971
- Chan EY-Y, Cheng CK-Y, Tam GC-H, Huang Z, Lee PY. Willingness of future A/H7N9 influenza vaccine uptake: A cross-sectional study of Hong Kong community. Vaccine. 2015;33: 4737–4740. doi: 10.1016/j.vaccine.2015.07.046
- 6. D. Cucinotta and M. Vanelli, "WHO declares COVID-19 a pandemic," Acta Biomed., vol. 91, no. 1, pp. 157-160, 2020, doi: 10.23750/abm.v91i1.9397.
- 7. Doshi D, Karunakar P, Sukhabogi JR, Prasanna JS, Mahajan SV. Assessing coronavirus fear in Indian population using the fear of COVID-19 scale. International journal of mental health and addiction. 2021 Dec;19. doi: (6):2383-91.
- 8. Dubé E. Addressing vaccine hesitancy: the crucial role of healthcare providers. Clinical Microbiology and Infection. 2017 May 1; doi: 23(5):279-80.
- 9. Gohel KH, Patel PB, Shah PM, Patel JR, Pandit N, Raut A. Knowledge and perceptions about COVID-19 among the medical and allied health science students in India: An online cross-sectional survey. Clinical epidemiology and global health. 2021 Jan 1;doi: 9:104-9.
- 10. Gupta R, Pal SK, Pandey G. A comprehensive analysis of COVID-19 outbreak situation in India. MedRxiv. 2020 Jan 1.
- K. Dhama, "Covid19 vaccine acceptance: Beliefs and barriers associated with vaccination among the general population in india," J. Exp. Biol. Agric. Sci., vol. 8, no. Special Issue 1, pp. S210-S, 2020, doi: 10.18006/2020.8(Spl-1-SARS-CoV-2). S210. S218
- 12. K. Sharun, C. K. Faslu Rahman, C. V. Haritha, B. Jose, R. Tiwari, and
- Kashte S, Gulbake A, El-Amin III SF, Gupta A. COVID-19 vaccines: rapid development, implications, challenges and future prospects. Human cell. 2021 May; doi: 34(3):711-33.
- 14. Kumar VM, Pandi-Perumal SR, Trakht I, Thyagarajan SP. Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases. npj Vaccines. 2021 Apr doi: 21;6(1):1-7.
- 15. Larson HJ, De Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, Cook AR, Jones NS. The state of vaccine confidence 2016: global insights

through a 67-country survey. EBioMedicine. 2016 Oct 1 doi: ;12:295-301.

- 16. Liyan Gao, Siman Su, Niuniu Du, Yu Han, Jiayi Wei, Meijuan Cao, Qunfang Miao, Xiaolei Wang Medical and non-medical students' knowledge, attitude and willingness towards the COVID-19 vaccine in China: a cross-sectional online survey, Human Vaccines & Immunotherapeutics, (2022) 18:5, 2073757,doi: 10.1080/21645515.2022.2073757
- 17. Mallapaty S. India's massive COVID surge puzzles scientists. Nature. 2021 Apr 21; doi: 592(7856):667-8.
- Omrani AS, Shalhoub S. Middle East respiratory syndrome coronavirus (MERS-CoV): what lessons can we learn?. Journal of hospital infection. 2015 Nov 1;doi: 91(3):188-96.
- 19. Pelly LP, Pierrynowski Macdougall DM, Halperin BA, Strang RA, Bowles SK, Baxendale DM, THEVAXED PROJECT: an assessment of immunization education in Canadian health professional programs. BMC Med Educ 2010;10:86
- 20. Peretti-Watel P. The management of health crises. Political and social issues. 2010(971).
- 21. Rackimuthu S, Hasan MM, Bardhan M, Essar MY. COVID-19 vaccination strategies and policies in India: the need for further re- evaluation is a pressing priority. The International Journal of Health Planning and Management. 2022 May; doi: 37(3):1847-50.
- 22. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz- Ospina E, Hasell J, Macdonald B, Beltekian D, Roser M. Coronavirus pandemic (COVID-19). Our world in data. 2020 Mar 5.
- 23. Sallam M. COVID-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates. Vaccines (Basel) 2021 Feb 16; 9 (2): 160. doi: 10.3390/vaccines9020160
- 24. Wang J, Jing R, Lai X, Zhang H, Lyu Y, Knoll MD. Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines. 2020;8: 482. doi:10.3390/vaccines8030482

| Distribution | Table 2 Distribution of each knowledge item among healthcare students and significant difference between socio-demographic characteristics | | | | | | | | | | | | | | | |
|--|--|---------|---------|----------|----------|---------------|-----------|------------|----------|----------|----|-------|-----|----|-------|-------------|
| Variables | Femal e | Male | χ2 | | | Sub- urban | | Pharmacy | | | | | | ĺ | ~? | P- value |
| Q. Have you | ever fe | lt conf | used a | bout the | numbe | r/ sche | duling o | of COVID-1 | 9 vaccin | e(s)? | | | | | | |
| Yes | 49 | 30 | | 44 | 20 | 15 | | 23 | 33 | 19 | 4 | | 69 | 10 | | |
| No | 213 | 170 | 0.11 | 178 | 125 | 82 | 10.269 | 120 | 116 | 112 | 35 | 5.175 | 346 | 37 | 2.149 | 0.00 |
| I am not sure | 68 | 66 | | 78 | 26 | 30 | | 39 | 42 | 42 | 11 | | 125 | 9 | | |
| Q. How long | do you | have | to wait | to recei | ve optim | al prote | ection fi | om the CO | VID-19 v | vaccine? | | | | | | |
| I don't know | 166 | 130 | | 143 | 92 | 61 | | 93 | 89 | 91 | 23 | | 278 | 18 | | |
| Immediately after the second dose of vaccination | 42 | 39 | | 40 | 26 | 15 | | 22 | 27 | 21 | 11 | | 71 | 10 | | |
| Two weeks after the firstdose of vaccination | | 45 | 1.071 | 63 | 20 | 25 | 7.518 | 31 | 37 | 31 | 9 | 5.399 | 96 | 12 | 8.305 | 0.00 |
| Two weeks after the | | 52 | | 52 | 33 | 26 | | 36 | 38 | 30 | 7 | | 95 | 16 | | |

| г <u></u> г | | | | | | | | | 1 | 1 | | | 1 | | 1 | |
|--------------------------|---------|----------|---------|----------|------------|-----------|----------|-------------|----------|--------|-----------|--------|-------|----------|-------|------|
| second dose of | | | | | | | | | | | | | | | | |
| vaccination | | | | | | | | | | | | | | | | |
| Q. Which sou | arce of | inform | ation | how sigr | nificantly | / impac | ted you | r opinion r | egarding | COVID- | 19 vaccin | ation? | | | | |
| 1. My doctor, | Healt | h care | provid | er | | | | | | | _ | | | | | |
| Very | | | | | | | | | | | | | | | | |
| U | 215 | 191 | | 201 | 117 | 88 | | 126 | 125 | 119 | 36 | | 366 | 40 | | |
| impact Somewhat | | | 3.982 | | | | 1.935 | | | | | 5.836 | | | 3.178 | 0.00 |
| | 83 | 59 | | 69 | 41 | 32 | | 39 | 55 | 37 | 11 | 5.050 | 133 | 9 | 5.170 | 0.00 |
| impact | | 0,0 | | 0,5 | 11 | 02 | | 0.5 | 00 | 5. | | | 100 | <u> </u> | | |
| Insignifican 3 | 32 | 16 | | 28 | 13 | 7 | | 17 | 11 | 17 | 3 | | 41 | 7 | | |
| t | | | | | | | | | | | | | | | | |
| impact | | 11 | | (77) | <u> </u> | | | | | | | | | | | |
| 2. My Univers | sity/Co | ollege, | Profes | sor/Tead | chers | | | | | | | | | | | |
| Very significant | 176 | 139 | | 158 | 92 | 65 | | 94 | 102 | 95 | 24 | | 283 | 32 | | |
| impact | 170 | 105 | | 100 | 54 | 00 | | 7 | 102 | 50 | 47 | | 200 | 52 | | |
| Somewhat | | | 0.413 | | | | 0.734 | | | | | 7.441 | | | 0.467 | 0.00 |
| significant 1 | 129 | 103 | | 115 | 64 | 53 | | 74 | 76 | 65 | 17 | | 212 | 20 | | |
| impact | | - | | | | | | | | | | | | | _ | |
| Insignificant2 | 25 | 24 | | 25 | 15 | 9 | | 14 | 13 | 13 | 9 | | 45 | 4 | | |
| impact 3. Governmei | nt web | oitos (1 | NHO I | | CL ICM | R MoH | FW etc |) | | | | | | | | |
| Very | III WCD | 51105 [| wii0, i | | | IX, 10111 | r w, cic | •) | | | | | | | | |
| | 191 | 176 | | 178 | 114 | 75 | | 119 | 118 | 100 | 30 | | 332 | 35 | | |
| impact | | | | | | | | | | | | | | | | |
| Somewhat | | | 4.81 | | | | 9.908 | | | | | 4.509 | | | 0.097 | 0.00 |
| 0 | 107 | 73 | | 86 | 49 | 45 | | 48 | 57 | 61 | 14 | | 163 | 17 | | |
| impact Insignifican 3 | 30 | 17 | | 34 | 8 | 7 | | 15 | 16 | 12 | 6 | | 45 | 4 | 1 | |
| t | 54 | 11 | | 57 | 0 | ' | | 15 | 10 | 12 | 0 | | -5 | 7 | | |
| impact | | | | | | | | | | | | | | | | |
| 4. Scientific J | Journa | ls/ Re | search | articles | | | | | | | | | | | | |
| Very | | | | | | | | | | | ~ - | | ~ ~ - | | | |
| | 173 | 142 | 1.418 | 160 | 94 | 61 | 6.189 | 100 | 105 | 85 | 25 | 2.919 | 285 | 30 | 0.198 | 0.00 |
| impact Somewhat | | | 1.410 | | | | 0.189 | | | | | 2.919 | | | 0.198 | 0.00 |
| | 116 | 99 | | 99 | 60 | 56 | | 60 | 69 | 67 | 19 | | 196 | 19 | | |
| impact | | | | | | | | | | | | | | | | |
| _ | _ | | _ | | | _ | | | | | | | | | | |
| Insignifican | ı 41 | 25 | | 39 | 17 | 10 | | 22 | 17 | 21 | 6 | | 59 | 7 | | |
| t | | | | | | | | | | | | | | | | |
| impact | | | | | | | | | | | | | | | | |
| 5. Immuno | comp | romis | ed pat | tients | | | | | | | | | | | | |
| Very | | | | | | | | | | | | | | | | |
| significant | 137 | 95 | | 115 | 73 | 44 | | 74 | 73 | 69 | 16 | | 206 | 26 | | |
| impact | | | | | | | | | | | | | | | | |
| Somewhat | | | 2.16 | | | | 3.474 | | | | | 4.57 | | | | 0.00 |
| significant | 138 | 120 | 3 | 126 | 69 | 63 | | 70 | 85 | 79 | 24 | | 238 | 20 | 3 | |
| impact | | | | | | | | | | | | | | | | |
| Insignifican | ı 55 | 51 | | 57 | 29 | 20 | | 38 | 33 | 25 | 10 | | 96 | 10 | | |
| t · | | | | | | | | | | | | | | | | |
| impact | | | | | | Ļ | | | | | | | | | | |
| 6. Mass me | dia (R | adio, ' | Felevi | sion. Ne | ewspap | er) | | | | | | | | | | |
| Very | | | | | | | | | | | | | | | | |
| significant | 176 | 142 | | 152 | 100 | 66 | | 102 | 102 | 88 | 26 | | 284 | 34 | | |
| impact | | | | | | | | | | | | 10.6 | 3 | | | |

| ignificant | 106 | Q / | 0.03 | 02 | 10 | 10 | 7.212 | 45 | 67 | 50 | 20 | 6 | 170 | 10 | 3.14 | 0.0 |
|--|--|--|---------------------------------|---|---|---|-----------------------------------|---|--|--|--|--------|---|--|-------------------|-----|
| significant mpact | 106 | 84 | 8 | 93 | 49 | 48 | | 45 | 67 | 58 | 20 | | 178 | 12 | 5 | |
| nsignifican | 48 | 40 | | 53 | 22 | 13 | | 35 | 22 | 27 | 4 | | 78 | 10 | | |
| npact | 1 | - 1: (| 1 | | 11 . | V1 / A | | | | 1 37 | | | | | | |
| . Online so | cial m | iedia (| such a | as Face | book, V | whatsA | pp, Tw | itter, In | stagram, | and Yo | uTube) | | | | | |
| 'ery ignificant npact | 180 | 150 | | 155 | 104 | 71 | | 105 | 104 | 93 | 28 | | 297 | 33 | | |
| omewhat gnificant npact | 103 | 87 | 1.48 2 | 98 | 47 | 45 | 6.268 | 51 | 65 | 58 | 16 | 2.152 | 174 | 16 | 0.35 7 | 0 |
| nsignifican npact | 47 | 29 | | 45 | 20 | 11 | | 26 | 22 | 22 | 6 | _ | 69 | 7 | | |
| . Other | | | | 1 | | | | | | | 1 | | | | | - |
| 'ery ignificant npact | 141 | 104 | | 118 | 78 | 49 | | 88 | 79 | 63 | 15 | 12.30 | 219 | 26 | | |
| omewhat gnificant npact | 121 | 108 | 1.07 2 | 110 | 58 | 61 | 9.78 | 55 | 78 | 70 | 26 | 6 | 211 | 18 | 1.08 8 | 0 |
| nsignifican | 68 | 54 | | 70 | 35 | 17 | | 39 | 34 | 40 | 9 | | 110 | 12 | | |
| npact | | | | | | | | | | | | | | | | |
| mpact 9. To your k | nowle | edge, p | olease | select | the opt | ion app | licable | for the | below sta | atement | s. | | | | | |
| | | | | | | | | | | | | | | | | |
| 2. To your k . COVID-19 trongly | 9 vacc 101 | ine ca 84 | | bit CO 88 | VID-19 52 | infecti 45 | | control 62 | its comp 56 | blication 51 | is. 16 | | 161 | 24 | | |
| 9. To your k . COVID-19 trongly gree | 9 vacc 101 125 | ine ca 84 121 | n inhi | bit CO 88 117 | VID-19 52 75 | infecti 45 54 | on and | control 62 75 | its comp 56 78 | 51 70 | 16 23 | 17.50 | 224 | 22 | | |
| . To your k . COVID-19 trongly gree gree | 9 vacc 101 125 87 | ine ca 84 121 54 | | bit CO 88 | VID-19 52 75 37 | infecti 45 | on and | control 62 | tits comp 56 78 51 | 51 51 70 40 | 16 23 11 | | 224 135 | 22 6 | 9.68 | С |
| 2. To your k . COVID-19 trongly gree gree fot sure bisagree | 9 vacc 101 125 87 12 | ine ca 84 121 54 4 | n inhi | bit CO 88 117 77 8 | VID-19 52 75 37 7 | infecti 45 54 27 1 | on and | control 62 75 39 6 | its comp 56 78 51 5 | 51 51 70 40 5 | 16 23 11 0 | 17.50 | 224 135 14 | 22 6 2 | 9.68 | 0 |
| 2. To your k . COVID-19 trongly gree gree ot sure visagree trongly | 9 vacc 101 125 87 | ine ca 84 121 54 | n inhi | bit CO 88 117 77 | VID-19 52 75 37 | infecti 45 54 | on and | control 62 75 39 | tits comp 56 78 51 | 51 51 70 40 | 16 23 11 | | 224 135 | 22 6 | -9.68 -6 | С |
| 2. To your k . COVID-19 trongly gree gree fot sure bisagree trongly isagree | 9 vacc 101 125 87 12 5 | ine ca 84 121 54 4 3 | n inhi 7.06 | bit CO 88 117 77 8 8 | VID-19 52 75 37 7 0 | infecti 45 54 27 1 0 | on and 13.81 8 | control 62 75 39 6 0 | its comp 56 78 51 5 1 | 51 51 70 40 5 7 | 16 23 11 0 | 17.50 | 224 135 14 | 22 6 2 | 9.68 | 0 |
| 2. To your k . COVID-19 trongly gree gree fot sure visagree trongly isagree . You can s trongly | 9 vacc 101 125 87 12 5 | ine ca 84 121 54 4 3 t COV 42 | n inhi 7.06 | bit CO 88 117 77 8 8 | VID-19 52 75 37 7 0 | infecti 45 54 27 1 0 | on and 13.81 8 | control 62 75 39 6 0 | its comp 56 78 51 5 1 | 51 51 70 40 5 7 | 16 23 11 0 | | 224 135 14 | 22 6 2 | 9.68 | c |
| 2. To your k . COVID-19 trongly gree gree fot sure bisagree trongly isagree . You can s trongly gree | 9 vacc 101 125 87 12 5 till ge | ine ca 84 121 54 4 3 t COV | n inhi 7.06 ID-19 | bit CO 88 117 77 8 8 8 after y | VID-19 52 75 37 7 0 vou hav | infecti 45 54 27 1 0 e been | on and -13.81 -8 vaccina | control 62 75 39 6 0 ated aga | its comp 56 78 51 5 1 ainst CO | Dication 51 70 40 5 7 VID-19 | 16 23 11 0 0 | _4 | 224 135 14 6 86 188 | 22 6 2 2 | _6 | |
| . To your k . COVID-19 trongly gree gree fot sure bisagree trongly isagree . You can s trongly gree gree | 9 vacc 101 125 87 12 5 till ge 55 | ine ca 84 121 54 4 3 t COV 42 | n inhi 7.06 ID-19 | bit CO 88 117 77 8 8 8 after y 44 | VID-19 52 75 37 7 0 vou hav 32 | infecti 45 54 27 1 0 e been 21 | on and | control 62 75 39 6 0 ated aga 29 | its comp 56 78 51 5 1 ainst CO 27 | Dication 51 70 40 5 7 7 VID-19 32 | IS. 16 23 11 0 0 9 | 17.50 | 224 135 14 6 86 188 | 22 6 2 2 11 | 9.68 | |
| 2. To your k . COVID-19 trongly gree gree fot sure bisagree trongly isagree . You can s trongly gree gree fot sure | 9 vacc 101 125 87 12 5 till ge 55 129 | ine ca 84 121 54 4 3 t COV 42 86 | n inhi 7.06 ID-19 9.81 | bit CO 88 117 77 8 8 8 44 95 | VID-19 52 75 37 7 0 vou hav 32 74 | infecti 45 54 27 1 0 e been 21 46 | on and | control 62 75 39 6 0 ated aga 29 67 | its comp 56 78 51 5 1 ainst CO 27 70 | Dication 51 70 40 5 7 VID-19 32 58 | IS. 16 23 11 0 0 9 20 | _4 | 224 135 14 6 86 188 | 22 6 2 2 11 27 | _6 | |
| 2. To your k . COVID-19 trongly gree gree lot sure Disagree trongly isagree . You can s trongly gree gree lot sure Disagree trongly isagree trongly isagree | vacc 101 125 87 12 5 5 129 113 22 11 | ine ca 84 121 54 4 3 t COV 42 86 114 22 2 | n inhi 7.06 ID-19 9.81 | bit CO 88 117 77 8 8 8 44 95 127 23 9 | VID-19 52 75 37 7 0 2 70 4 32 74 53 10 2 | infecti 45 54 27 1 0 e been 21 46 47 11 2 | on and | control 62 75 39 6 0 29 67 75 8 3 | its comp 56 78 51 5 1 27 27 70 77 13 4 | Discription 51 70 40 5 7 VID-19 32 58 57 20 6 | IS. 16 23 11 0 0 9 20 18 3 0 | -4 | 224 135 14 6 86 188 213 42 11 | 22 6 2 2 11 27 14 2 2 2 | -6 -7.49 -9 | |
| 2. To your k 2. To your k 3. COVID-19 4. trongly gree gree dot sure bisagree trongly isagree gree gree fot sure bisagree bisagree trongly gree gree trongly gree isagree trongly isagree trongly isagree trongly isagree trongly isagree The COVI | vacc 101 125 87 12 5 till ge 55 129 113 22 11 D-19 | ine ca 84 121 54 4 3 t COV 42 86 114 22 2 vaccin | n inhi 7.06 ID-19 9.81 | bit CO 88 117 77 8 8 8 8 44 95 127 23 9 9 won't : | VID-19 52 75 37 7 0 vou hav 32 74 53 10 2 2 make y | infecti 45 54 27 1 0 e been 21 46 47 11 2 ou test | vaccina 11.71 positiv | control 62 75 39 6 0 29 67 75 8 3 3 e. COVI | its comp 56 78 51 5 1 27 70 77 13 4 iD-19 vir | bilication 51 70 40 5 7 VID-19 32 58 57 20 6 us testin | IS. 16 23 11 0 0 9 20 18 3 0 | 4 | 224 135 14 6 86 188 213 42 11 for CC | 22 6 2 2 11 27 14 2 2 2 VID- | -6 -7.49 -9 | |
|). To your k | vacc 101 125 87 12 5 5 129 113 22 11 | ine ca 84 121 54 4 3 t COV 42 86 114 22 2 | n inhi 7.06 ID-19 9.81 | bit CO 88 117 77 8 8 8 44 95 127 23 9 | VID-19 52 75 37 7 0 2 70 4 32 74 53 10 2 | infecti 45 54 27 1 0 e been 21 46 47 11 2 | vaccina 11.71 positiv | control 62 75 39 6 0 29 67 75 8 3 | its comp 56 78 51 5 1 27 27 70 77 13 4 | Discription 51 70 40 5 7 VID-19 32 58 57 20 6 | IS. 16 23 11 0 0 9 20 18 3 0 | -4 | 224 135 14 6 86 188 213 42 11 for CC | 22 6 2 2 11 27 14 2 2 2 | -6 -7.49 -9 | |

| Disagree | 37 | 32 | [/ | 32 | 25 | 12 | | 22 | 20 | 20 |) 7 | 7 | | 58 | 11 | | | |
|----------------------|----------|---------|---------|----------|----------|----------|-----------------|-----------------|-------------------|--------------|---------|----------|-----------|---------|---------|--------|------------|-------|
| 0 | | 6 | 1 1 | 14 | 4 | 3 | - | 22 | 5 | 12 | | - | 1 | 17 | 4 | | | |
| 4. Mass CO | | | | on play | s a cru | acial ro | ole in <i>e</i> | achievi | ng herd | immv | anity i | n the | popula | ation ' | than i | immu | nity | |
| acquired th | - | | | | | | | | | | | | | | | | | |
| Strongly agree | 81 | 50 | | 56 | 42 | 33 | | 44 | 37 | 35 | 1 | 15 | | 110 | 21 | | | |
| Agree | | 111 | - | | 61 | 59 | | 62 | 82 | 55 | | 15 | | | 12 | | | |
| Not sure | | - | _ | 114 | 54 | 28 | _ | 66 | 54 | 58 | | | 20.75 | | 15 | | 0. | |
| 0 | | | _ | | 11 | 0 | _ | 7 | 12 | 12 | | | | | 4 | 7 | 00 | |
| Strongly disagree | 19 | 4 | 2 | 16 | 3 | 4 | | 3 | 6 | 13 | 1 | | | 19 | 4 | | | |
| 5. Children | under | 18 ye: | ars of | age sho | ould ge | t COVI | D-19 v | accina | tion onc | e as s | oon as | s they a | are eliş | zible f | or it. | | | |
| Strongly | | 98 | | | | 47 | | 63 | 74 | 55 | | 21 | | | 24 | | | |
| | 101 | 108 | | 98 | 61 | 50 | | 70 | 65 | 58 | 1 | 16 | (/ | 190 | 19 | | | |
| | | | | | 31 | | 15.03 | | 38 | 39 | | 12 | 14.87 | 123 | | 7.15 | 0. | |
| | | | | | 4 | | ~ | 6 | 9 | 9 | 1 | | _ | | - | | 00 | |
| Strop altr | | 4 | | - | 3 | 4 | | 3 | 5 | 12 | 2 0 |) | | 16 | 4 | | | |
| Q. Have yo | u attene | ded ar | ny of t | he disc | ussion | s/lect | ures re | gardin | g the CC |)VID-1 | 9 vac | cine? | | | | | | |
| | | 128 | | | | 67 | | 81 | 95 | 74 | | 27 | | 250 | 27 | | | |
| | | 111 | | | | 47 | | 80 | 80 | 74 | | 20 | | | 21 | | | |
| I do not | | | 0.62 | | 13 | | 9.867 | | 16 | 25 | | | 6.174 | | | 1.06 | 0. | |
| University | | [] | | í í | | | | | | | | | | | | | 00 | |
| lectures | | | | | | | | | | | | | | | | | | |
| currently. | | | | | | | | | | | | | (' | | | | | |
| Distri | bution (| of eacl | h attit | ude iter | m amo: | ng hea' | lthcare | Table studer | le 4 nts and s | signifi | cant d | lifferer | ice bet | ween | socio- | demo | grapł | hic |
| | | | | | | -0 | | | eristics | | | | | | | | , | |
| | | | | | | (| Sub- | | | Indi | | Oth | | | | | <i>P</i> - | |
| Variable | es | ale er | Ĩ | χ2 | Urbanu | 1 | 11 | χ2 ε | acy | /ledi cal | arsing | ers | χ2 | PG | | χ2 | Va | alue |
| Q. Pleas view) | se selec | t the | option | which | is app | licable | ; for th | e belov | w statem | nents. | (Selec | t the o | option | that : | reflect | s you | r poi | int c |
| | | cate n | nyself | about | COVID |)-19 va | iccines | for bo | oth me a | and m | ıy futı | ure pa | tients | as an | ı aspir | ring h | ealth | ncar |
| Strongly Agree | | .67 1 | 67 | | 151 1 | 108 | 75 | | 112 | 101 | 95 | 26 | | 300 | 0 34 | | | |
| Agree | 1 | .04 7 | 79 | | 94 5 | 50 3 | 39 | 14.02 | 52 | 63 | 47 | 21 | 175 | 167 | 7 16 | 1 | | |
| Not sure | , | | .5 | 4 | | | 11 | 5 | | 23 | 19 | 3 | 17.5 8 | 56 | 3 | 2.94 | 6 0.0 | 00 |
| Disagree | | | | | - | - | 1 | | | 2 | 6 | 0 | | 8 | 2 | | | |
| Strongly disagree | • | Ŭ | | | | | 1 | | | 2 | 6 | 0 | | 9 | 1 | | | |
| | | it my (| doctor | or heat | lth care | e provi | der rec | omme | nds abou | at the | COVI | D -19 v | vaccin | e. | | | | |
| Strongly Agree | 1 | .27 1 | 45 | | 118 9 | 97 | 57 | | 82 | 83 | 77 | 30 | | 245 | 5 27 | | T | |
| Agree | 1 | .46 9 | 99 | , F | 129 6 | 60 5 | 56 | f | 82 | 81 | 66 | 16 | - | 222 | 2 23 | | | |
| Agree | | 86 1 | 17 | 20.75 | 32 1 | 10 | 11 | 19.73 | 12 | 19 | 18 | 4 | 13.5 | 57 52 | | 10 00 | 0.0 | 20 |

| Disagree | 13 | 2 | | 11 | 1 | 3 | 4 | 2 | 5 | 8 | 0 | 7 | 13 | 2 | | |
|---------------------------|--------------|------------|------------|------------|----------|----------|------------|-----------|----------|----------|----------|------------|------------|--------|------------|---------|
| Strongly disagree | 8 | 3 | ł | 8 | 3 | 0 | | 4 | 3 | 4 | 0 | ł | 8 | 3 | | |
| 3. I will rec | comme | nd the | COVIE |)-19 v | accine | to my | fellow | studer | its/ fri | iends/fa | mily/ | relative | e and | futu | ire hea | lthcare |
| Strongly Agree | 150 | 147 | | 123 | 108 | 66 | | 92 | 85 | 94 | 26 | | 267 | 30 | | |
| Agree | 110 | 89 | 12.58 | 106 | 49 | 44 | 32.04 | 66 | 72 | 42 | 19 | 19.59 | 182 | 17 | | |
| Not sure | 50 | 18 | 6 | 44 | 9 | 15 | 6 | 15 | 27 | 22 | 4 | 3 | 64 | 4 | 2.79 | 0.00 |
| Disagree | 12 | 7 | | 15 | 2 | 2 | | 7 | 3 | 8 | 1 | | 16 | 3 | | |
| Strongly | 8 | 5 | | 10 | 3 | 0 | | 2 | 4 | 7 | 0 | | 11 | 2 | | |
| disagree 4. I think me | ost of tl | he stud | ents at | my ur | niversit | y/colle | ge will | get a CC | OVID-1 | 9 vaccin | e if it | is recor | mmer | nded : | for the | n |
| Strongly Agree | 137 | 140 | | 118 | 98 | 61 | | 76 | 85 | 85 | 31 | - | 248 | 29 | | |
| Agree | 128 | 94 | 12.02 | 115 | 60 | 47 | _ | 79 | 75 | 54 | 14 | | 204 | 18 | | |
| Not sure | 41 | 23 | 7 | 41 | 9 | 14 | 5 | 22 | 20 | 17 | 5 | 20.43 | 62 | 2 | 9.177 | 0.00 |
| Disagree | 12 | 7 | | 14 | 3 | 2 | | 3 | 6 | 10 | 0 | ĺ | 15 | 4 | | |
| Strongly disagree | 12 | 2 | | 10 | 1 | 3 | | 2 | 5 | 7 | 0 | | 11 | 3 | | |
| 5. All health | care pr | ofessio | nals an | d stud | ents sł | hould t | e requi | ired to g | et the (| COVID-1 | 9 vac | cine. | | | | |
| Strongly Agree | 147 | 137 | | 125 | 97 | 62 | | 91 | 84 | 85 | 24 | | 252 | 32 | | |
| Agree | 116 | 97 | | 107 | 61 | 45 | | 69 | 73 | 50 | 21 | 10.46 | 196 | 17 | 10.00 | 0.00 |
| Not sure | 46 | 22 | 7.656 | 42 | 11 | 15 | 21.60 3 | 16 | 26 | 21 | 5 | 19.46 5 | 67 | 1 | 10.66 2 | 0.00 |
| Disagree | 9 | 4 | | 11 | 0 | 2 |] | 2 | 5 | 6 | 0 | | 10 | 3 | | |
| Strongly disagree | 12 | 6 | | 13 | 2 | 3 | | 4 | 3 | 11 | 0 | | 15 | 3 | | |
| 6. For the ge | eneral p | oublic, (| COVID- | 19 im | muniza | tion sł | nould b | e manda | ated. | | | | | | | |
| Strongly Agree | 149 | 133 | | 118 | 101 | 63 | | 88 | 85 | 81 | 28 | | 249 | 33 | | |
| Agree | 111 | 102 | 11.75 | 115 | 54 | 44 | 21.84 | 66 | 74 | 58 | 15 | 15.91 | 198 | 15 | | |
| Not sure | 46 | 20 | 2 | 40 | 12 | 14 | 6 | 19 | 23 | 17 | 7 | 7 | 64 | 2 | 9.612 | 0.00 |
| Disagree | 13 | 9 | | 15 | 3 | 4 | | 7 | 7 | 8 | 0 | | 19 | 3 | | |
| Strongly disagree | 11 | 2 | | 10 | 1 | 2 | | 2 | 2 | 9 | 0 | | 10 | 3 | | |
| 7. Children u | nder th | | f 18 sh | ould b | | elled to | o get Ci | 10 בוער | immu | nizotion | | | | • | | |
| Strongly Agree | | 105 | | 104 | 76 | 51 | | 72 | 68 | 70 | 21 | | 204 | 27 | | |
| gree | 111 | 108 | | 111 | 63 | 45 |] | 69 | 74 | 58 | 18 | | 202 | | | |
| lot sure Disagree | 57 18 | 42 7 | 11.22 9 | 52 19 | 25 2 | 22 4 | 11.11 5 | 27 8 | 34 10 | 28 7 | 10 0 | 8.153 | 92 | 7 | 2.943 | 0.00 |
| trongly | 18 | 4 | | $19 \\ 12$ | 5 | 5 | | o 6 | 5 | 10 | 1 | | 22 | 2 | 2.510 | 0.00 |
| isagree | | | | | - | | | | - | | | | | | | |
| 8. I want to ta | | | clinica | | | | ID-19 v | | | | 10 | | 107 | 10 | | |
| trongly Agree | e 106 128 | 110 110 | | 95 124 | 71 65 | 50 49 | _ | 68 75 | 64 76 | 65 64 | 19 23 | - | 197 215 | | - | |
| gicc | 120 | 110 | | 124 | 05 | 77 | | 15 | 10 | 04 | 23 | | 213 | 23 | | |

| Not sure | 50 | 35 | 20.31 | 45 | 22 | 18 | | 25 | 33 | 21 | 6 | 10.16 | 80 | 5 | | |
|----------------|--------|---------|----------|--------|---------|---------|---------|-----------|---------|-----------|-----|-------|-----|----|-------|------|
| Disagree | 22 | 8 | 1 | 20 | 7 | 3 | 8.48 | 7 | 9 | 14 | 0 | 1 | 26 | 4 | 4.53 | 0.00 |
| Strongly | 24 | 3 | | 14 | 6 | 7 | | 7 | 9 | 9 | 2 | | 22 | 5 | | |
| disagree | | | | | | | | | | | | | | | | |
| Q. Would you d | escrib | e yours | elf as b | eing p | ro-vacc | inatior | n or an | ti-vaccin | ation c | or neutra | al? | | | | | |
| Anti | 103 | 81 | | 108 | 49 | 27 | 10.20 | 60 | 64 | 46 | 14 | | 173 | 11 | | |
| Neutral | 107 | 83 | 0.252 | 90 | 54 | 46 | 3 | 48 | 69 | 57 | 16 | 8.301 | 175 | 15 | 7.449 | 0.00 |
| Pro | 120 | 102 | | 100 | 68 | 54 | | 74 | 58 | 70 | 20 | | 192 | 30 | | |

| Т | Distributi | on of ea | uch perce | ention i | item a | mongh | Tabl | | ente an | d sign | ificant | differ | ence h | etwee | en socio- | |
|-------------|-----------------|----------|------------|----------|-----------------|----------|-----------|--------------|-------------|-------------|------------|--------|--------|-------|-----------|-----------------|
| 1 | Distributi | | | | | | aphic cl | | | iu sign | incam | | | | | |
| 00 | | | χ2 | rban | | uibali | χ2 | Phar macy | Med ical | Nur sing | Oth ers | χ2 | PG | UG | χ2 | P- valu e |
| | s getting | | D-19 vac | cine to | o indic | ate that | you sh | ould ste | op | | | | | | | |
| | ring a ma | | | | 1 | <u> </u> | 1 | 1 | | 1 | | | | 1 | | |
| | 202 | 150 | 10 704 | 181 | 99 | 72 | 4.060 | 116 | 106 | 101 | 29 | 5.89 | 318 | 34 | 0.005 | 0.00 |
| No | 97 | 110 | 18.734 | 94 | 64 | 49 6 | 4.263 | 56 | 75 | 57 | 19 | 6 | 189 | 18 | 0.235 | 0.00 |
| Not sure | 31 | 6 | | 23 | 8 | 6 | | 10 | 10 | 15 | 2 | | 33 | 4 | | |
| | ticing Ph | voico1/S | Social dis | toncin | <u>م</u> | | | | | | | | | | | |
| | 204 | 153 | | 170 | <u>g</u> 109 | 78 | | 114 | 110 | 105 | 28 | 3.99 | 325 | 32 | | |
| No | 104 | 100 | 2.839 | 101 | 57 | 46 | 11.426 | | 72 | 55 | 20 | 1 | 181 | | 2.682 | 0.00 |
| Not | 22 | 13 | | 27 | 5 | 3 | 11.120 | 11 | 9 | 13 | 20 | - | 34 | 1 | | 0.00 |
| sure | | - 0 | | _ · | | - | | | | 10 | | | | - | | |
| | ig alcohol | -based | hand sai | hitizers | 5 | | | | | | | | | | | |
| Yes | 200 | 154 | | 181 | 98 | 75 | | 111 | 113 | 101 | 29 | 4.33 | 324 | 30 | | |
| No | 102 | 102 | 7.72 | 89 | 68 | 47 | 12.337 | 60 | 69 | 56 | 19 | 6 | 182 | 22 | 0.872 | 0.00 |
| Not | 28 | 10 | | 28 | 5 | 5 | | 11 | 9 | 16 | 2 | | 34 | 4 | | |
| sure | | | | | | | | | | | | | | | | |
| 4. Havi | ing to avo | | gatherir | | owded | | | | | | | _ | | | | |
| Yes | 211 | 168 | | 185 | 110 | 84 | | 122 | 116 | 113 | 28 | 7.36 | 347 | 32 | _ | |
| | 80 | 81 | 6.733 | 70 | 53 | 38 | 19.136 | | 56 | 39 | 18 | 9 | 140 | | 3.993 | 0.00 |
| Not | 39 | 17 | | 43 | 8 | 5 | | 12 | 19 | 21 | 4 | | 53 | 3 | | |
| sure | | <u> </u> | <u> </u> | | | | | L | | | | | | | | |
| | se select | | | | | | | | ents. | | | | | | | |
| 1. I thu | nk COVII 131 | | ccines st | | | | ie syster | | 77 1 | 69 | 10 | T | 615 | 64 | T | |
| Strong | | 108 | | 120 | 65 | 54 | | 80 | 71 | 09 | 19 | | 215 | 24 | | |
| ly | | | | | | | | | | | | 8.11 | | | | |
| 1.y | | | 5.766 | | | | 7.924 | | | | | 4 | | | 3.318 | 0.00 |
| Agree | | | 01100 | | | | | | | | | 1 | | | 0.010 | 0.00 |
| 0 | 128 | 117 | | 114 | 81 | 50 | | 71 | 88 | 65 | 21 | | 223 | 22 | | |
| Agree | | | | | | | | | | | | | | | | |
| Not | 60 | 35 | | 56 | 19 | 20 | | 26 | 27 | 33 | 9 | | 88 | 7 | | |
| sure | | | | | | | | | | | | | | | | |
| | 8 | 6 | | 6 | 5 | 3 | | 3 | 5 | 5 | 1 | | 11 | 3 | | |
| Disagr | | | | | | | | | | | | | | | | |
| ee | 0 | 0 | _ | 0 | 1 | 0 | - | 0 | 0 | 1 | 0 | _ | 0 | 0 | _ | |
| Church | 3 | 0 | | 2 | 1 | 0 | | 2 | 0 | 1 | 0 | | 3 | 0 | | |
| Strong | | | | | | | | | | | | | | | | |
| ly | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |

| disagre | | | | | | | | | | | | | | | | |
|-------------------------|------------|------------|----------|-----------|--------|------------|-----------|-----------|----------|---------|---------|------------|-----------|---------|-------|------|
| e – | | | | | | | | | | | | | | | | |
| | future he | | | | gettin | g the CO | OVID-19 | vaccina | ation i | s cruci | | | | | 1 | |
| Strong ly Agree | | 118 | 9.772 | 112 | 74 | 57 | 7.119 | 76 | 75 | 73 | 19 | 13.1 98 | 222 | 21 | 8.307 | 0.00 |
| | 131 | 112 | | 125 | 67 | 51 | | 75 | 84 | 60 | 24 | | 215 | 28 | | |
| Not | 58 | 32 | | 47 | 26 | 17 | | 25 | 29 | 29 | 7 | | 86 | 4 | | |
| sure Disagr ee | 10 | 2 | | 7 | 3 | 2 | | 3 | 3 | 6 | 0 | | 9 | 3 | | |
| Strong ly disagre | 6 | 2 | | 7 | 1 | 0 | | 3 | 0 | 5 | 0 | | 8 | 0 | | |
| c 3. It wil | ll be cruc | ial for th | ne gener | al publ | ic hea | lth of oı | ur comn | nunities | to hav | ve the | COVIE |)-19 va | accina | tion. | | 1 |
| | | 136 | | 112 | | 64 | 15.446 | 85 | 74 | | 28 | 13.7 98 | | 24 | 1.776 | 0.00 |
| | 134 | 99 | | 122 | 63 | 48 | | 67 | 83 | 65 | 18 | | 210 | 23 | | |
| | 56 | 30 | | | | 14 | | 25 | 30 | | 4 | | | 6 | | |
| Disagr ee | 11 | 1 | | 8 | 3 | 1 | | 3 | 4 | 5 | 0 | | 10 | 2 | | |
| | 6 | 0 | | 6 | 0 | 0 | | 2 | 0 | 4 | 0 | | 5 | 1 | | |
| disagre e | | | | | | | | | | | | | | | | |
| 4. If the | e WHO or | the FD. | A approv | ves the | COVI | D-19 va | ccine, it | t will be | effecti | ve. | | | | | | |
| Strong ly | | 101 | 15.486 | 108 | 67 | 48 | 9.801 | 73 | 68 | 66 | 16 | 10.3 79 | 202 | 21 | 8.992 | 0.00 |
| Agree | 100 | 110 | | 110 | | F 4 | | 70 | 00 | 60 | 05 | | 000 | 05 | | |
| Agree Not | 126 59 | 119 44 | | 116 57 | | 54 19 | | 72 31 | 80 38 | | 25 8 | | 220 98 | 25 5 | | |
| sure | | | | | | | | | | | | | | | | |
| Disagr ee | | 2 | | 13 | 1 | 6 | | 5 | | | 1 | | | 3 | | |
| | 5 | 0 | | 4 | 1 | 0 | | 1 | 1 | 3 | 0 | | 3 | 2 | | |
| disagre e | | | | | | | | | | | | | | | | |

| 5. The benefits of the COVID-19 vaccine outweigh the risks or side effects | | | | | | | | | | | | | | | | |
|--|-------------|----------|------------|----------|------------|----------|----------|---------|----------|---------|----|------|-----------|---------|-------|------|
| | | 78 | | | | 10 | | 60 | | 48 | 16 | | 152 2 | 21 | | |
| Strong | | | | | | | | | | | | 9.62 | | | | |
| ly | | | 2.676 | | | ŕ | 7.829 | | | | | 2 | | 5 | .484 | 0.00 |
| Agree | | | | | | | | | | | | | | | | |
| | 125 | 99 | | 112 6 | 6 4 | 16 | | 66 | 78 | 59 | 21 | c. | 203 2 | 21 | | |
| Not | | 76 | | | | 35 | | 44 | | | 12 | | 155 9 | | | |
| sure | | _ | | | | | | | - | _ | | | | | | |
| Disagr | 12 | 10 | | 13 4 | + 5 | 5 | | 7 | 8 | 6 | 1 | 1 | 19 3 | 3 | | |
| ee | | | | | | | | | | | | | | | | |
| | 4.0 | | | 4.0 | | 1. | | 1- | | | | | | 6 | | |
| Strongly | | 3 | | 10 | 2 | 1 | | 5 | 2 | 6 | 0 | | 11 | 2 | | |
| disagree 6 Lthin | k life will | l come h | acle to 't | | ן 10 10 |) norma | 1' post | COVID | 10 100 | | | | | | | |
| 0.1 1111 | 108 | 72 | ack in p | 87 | 56 | 37 | ii post- | 70 | 48 | 48 | 14 | | 158 | 22 | | |
| Strongly | | | | 0. | 00 | 0. | | | | | 1 | | 100 | | | |
| Agree | e | | | | | | | | | | | 19.1 | | | | |
| Agree | e 128 | 101 | 9.164 | 109 | 67 | 53 | 8.774 | 65 | 76 | 65 | 23 | 65 | 210 | 19 | 3.167 | 0.00 |
| Not sur | | 86 | | 83 | 45 | 34 | _ | 42 | 60 | 47 | 13 | _ | 150 | 12 | | |
| Disagre | e14 | 5 | | 14 | 2 | 3 | _ | 5 | 5 | 9 | 0 | _ | 17 | 2 | _ | |
| 0, 1 | 4 | 2 | | 5 | 1 | 0 | | 0 | 2 | 4 | 0 | | 5 | 1 | | |
| Strongly | y | | | | | | | | | | | | | | | |
| disagree | 2 | | | | | | | | | | | | | | | |
| | COVID-19 | vaccin | e will be | effectiv | e for o | childrer | n under | 18 year | rs of ag | ge. | | | 1 | | | |
| | 98 | 71 | | 77 | 53 | 39 | | 55 | 53 | 48 | 13 | | 148 | 21 | | |
| Strongly | | | | | | | | | | | | | | | | |
| Agree | | | 1 | | | | | | | | | 6.55 | | | | 0.00 |
| Agree | | 108 | 1.453 | 121 | 62 | 50 | 4.639 | 71 | 80 | 61 | 21 | 9 | 213 | - | 3.442 | 0.00 |
| Not sur | e 87 9 | 73 8 | _ | 80 9 | 46 5 | 34 3 | | 45 6 | 49 5 | 51 5 | 15 | - | 149 15 | 11 2 | - | |
| Disagre | - | ð | | 9 | 3 | 3 | | 0 | Э | Э | 1 | | 15 | 2 | | |
| Disagie | 11 | 6 | | 11 | 5 | 1 | | 5 | 4 | 8 | 0 | | 15 | 2 | | |
| Strongly | | Ŭ | | * * | | - | | Ŭ | | Ŭ | Ŭ | | 10 | | | |
| 0. | | | | | | | | | | | | | | | | |
| disagree | e | | | | | | | | | | | | | | | |